Journal Article

Determination of Acepromazine, Ketamine, Medetomidine, and Xylazine in Serum: Multi-Residue Screening by Liquid Chromatography-Mass Spectrometry

Irina Rudik Miksa, Margaret R. Cummings and Robert H. Poppenga

in Journal of Analytical Toxicology

Volume 29, issue 6, pages 544-551
Published in print September 2005 | ISSN: 0146-4760
Published online September 2005 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/29.6.544
Determination of Acepromazine, Ketamine, Medetomidine, and Xylazine in Serum: Multi-Residue Screening by Liquid Chromatography-Mass Spectrometry

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

A large variety of drugs are administered to large and small animals by veterinary clinicians for sedation, anesthesia, muscle relaxation, and analgesia. The present paper reports a simple and rapid multi-residue detection and quantitation method for four chemically different drugs: medetomidine, xylazine, ketamine, and acepromazine. Chromatographic separation was carried out on a liquid chromatography-mass spectrometry instrument with a C18-reversed-phase column. Fragmentation patterns were determined with atmospheric pressure chemical ionization mass spectrometry set to operate in a positive selective ion monitoring mode. The method was determined to be linear over the range of concentrations tested (2.0–100.0 ng/mL). Accuracy, precision, and specificity were evaluated and the method was determined to be applicable to detection of medetomidine, xylazine, ketamine, and acepromazine in serum samples of multiple animal species (canine, equine, and bovine). Matrix limits of quantitation were determined to be 5.0 ng/mL for all four analytes, and recoveries ranged between 82.0 and 118%, with a 3.0–18.3% relative standard deviation.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.